Publication Name	World Journal of Transplantation
Manuscript ID	5319
Country	China

Received	2013-08-29 09:19
Peer-Review Started	2013-08-29 16:39
To Make the First Decision	2013-09-09 14:29
Return for Revision	2013-09-11 11:06
Revised	2013-11-15 23:27
Second Decision	2013-12-10 16:30
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2013-12-11 09:13
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-12-25 17:11
Publish the Manuscript Online	2013-12-31 17:17

ISSN	2220-3230 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Transplantation
Manuscript Type	Review
Article Title	Optimal stem cell source for allogeneic stem cell transplantation for hematological malignancies
Manuscript Source	Invited Manuscript
All Author List	Daniel KL Cheuk
Funding Agency and Grant Number	Funding Agency Grant Number University of Hong Kong
Corresponding Author	Daniel KL Cheuk, FHKAM, Department of Paediatrics and Adolescent Medicine, the University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong, China. cheukkld@hkucc.hku.hk
Key Words	Hematopoietic stem cell transplantation; Bone marrow; Peripheral blood stem cell; Cord blood; Hematological malignancy
Core Tip	Core tip: Randomized controlled trials (RCTs) suggest no difference in survival between peripheral blood stem cell (PBSC) and bone marrow (BM) in matched sibling transplant for patients with hematological malignancies. PBSC may result in fewer relapse in high risk patients but more severe graft-versus-host disease (GVHD). For unrelated donor, the only RCT suggests PBSC and BM result in comparable survivals, with PBSC resulting in fewer graft failure but more chronic GVHD. RCT is not available to compare cord blood with BM or PBSC. The risks and benefits of different sources of stem cells likely change with transplant methods and manipulation of grafts.
Publish Date	2013-12-31 17:17
Citation	Cheuk DKL. Optimal stem cell source for allogeneic stem cell transplantation for hematological malignancies. World J Transplant 2013; 3(4): 99-112
URL	http://www.wjgnet.com/2220-3230/full/v3/i4/99.htm
DOI	http://dx.doi.org/10.5500/wjt.v3.i4.99

Full Article (PDF)	WJT-3-99.pdf
Full Article (Word)	WJT-3-99.doc
Manuscript File	5319-Review.doc
Answering Reviewers	5319-Answering reviewers.pdf
Copyright License Agreement	5319-Copyright assignment.pdf
Peer-review Report	5319-Peer review(s).pdf
Scientific Editor Work List	5319-Scientific editor work list.doc